natgillin/translations-raw huggingface dataset:
The process of claim 1, wherein at least a portion of the process for preparing 1,1,1,2,3-pentachloropropane occurs in equipment comprising a reaction zone, a separation zone optionally comprising a distillation component, and a condensing zone. 
Postupak iz patentnog zahtjeva 1, pri čemu se barem dio postupka odvija u opremi koja obuhvaća reakcijsku zonu, zonu razdvajanja i zonu kondenzacije. Postupak iz patentnog zahtjeva 5, pri čemu zona razdvajanja obuhvaća odjeljak za destilaciju.
1.96 or Figure 9 or 10, wherein the X-Ray Powder Diffraction data is collected on a diffractometer operating with a copper anode and a nickel filter. 
[image] Ili slici 9 ili 10, pri čemu su podaci o difrakciji X-zraka na praškastom uzorku dobijeni pomoću difraktometra sa bakarnom anodom i filterom od nikla.
the carbon-containing compound comprises glycerol, polyethylene glycol having a molar mass of from 380 to 420, or a mixture of the two; and carbon of the carbon-containing compound is used in a molar ratio to Cr(VI) of from 9:1 to 23:1. 
Postupak prema zahtjevu 1, naznačen time da glicerol, polietilen glikol imaju molarnu masu od 380 do 420 ili smjesa njih dva se koristi kao spoj koji sadrži ugljik naveden u koraku a) i time da se ugljik iz spoja koji sadrži ugljik naveden u koraku a) koristi u molarnom odnosu prema Cr(VI) od 9:1 do 23:1.
is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two substituents selected from halo, alkoxy, hydroxymethyl and alkyl; and 
Rs je piridil, pirazinil, benzoksazolil, piridazinil, naftiridinil ili pirimidinil, pri čemu piridil, pirazinil, benzoksazolil, piridazinil, naftiridinil ili pirimidinil je proizvoljno supstituiran s do dva supstituenta odabrana iz skupine koju čine halo, alkoksi, hidroksimetil i alkil; i zvonom
Analogous results to those described in Examples 1 and 2 were obtained. 
Dobiju se analogni rezultati kako je opisano u Primjerima 1 12.
Figure 6 shows a top view of the electronic circuit (S1.3) constituted by circuits (S1.3.1) comprising the contact points (S1.3.1.1). 
navedeni strujni krug (S1.3) sadrži: - krug (S1.3.1) koji integrira kontaktne točke (S1.3.1.1), -
"Alkyn" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having 2 to 15 carbon atoms in the chain. 
"Alkin" znači alifatska ugljikovodična skupina s trostrukom vezom ugljik-ugljik, a može biti nerazgranata ili razgranata, s 2 do 15 ugljikovih atoma u lancu.
The method of claim 1, wherein the therapeutically effective amount of the compound of Formula (I) is contained within a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or excipient. 
Farmaceutska smjesa koja sadrži terapijski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 8 i farmaceutski prihvatljivi nosač ili pomoćnu tvar.
A capsule according to any one of claims 1-5, wherein the at least one projection is provided on separate regions along a periphery of the capsule. 
Kapsula prema jednom od patentnih zahtjeva 1-3, pri čemu najmanje jedan ispupčeni dio (127) postoji na odvojenim područjima duž periferije kapsule (110).
The IL-17 antagonist for use according to Claim 8, wherein the IL-17 antagonist is a humanized monoclonal antibody or a fully human monoclonal antibody. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 8, naznačen time, da IL-17 antagonist je humanizirano monoklonsko antitijelo ili potpuno ljudsko monoklonsko antitijelo.
A pharmaceutical composition for preventing or treating a metabolic syndrome, comprising a compound of the following Formula (I'), a pharmaceutically acceptable salt, or a solvate thereof: in the formula, 
Spoj 22,4 Spoj 23 Spoj sljedeće formule I). ili njegova farmaceutski prihvatljiva sol, za primjenu u prevenciji ili liječenju metaboličkog sindroma: u formuli,
The aqueous pharmaceutical composition of any one of the preceding claims, wherein the composition is provided as a single-dose volume of less than 5 ml. 
Sastav za upotrebu prema patentnom zahtjevu 1, pri čemu je sastav administriran u pojedinačnoj dozi čija je zapremnina manja od 5 ml ili manja od 3 ml.
mL of filtrate was collected and applied to a 70 g, 5 x 6.5 cm C18-RP SPE bed (Supelco® LC-18 material) that had been conditioned with 50% (v/v) ethanol/water and percolated with 200 mL distilled water before usage. 
150 mL filtrata se sakupi i nanese na 70 g, 5 x 6,5 cm C18-RP SPE ploču (Supelco" LC-18 materijal) koja je kondicionirana s 50%-tnim (v/v) etanolom/vodom i perkolirana s 200 mL destilirane vode prije upotrebe.
In another example, the process is according to the preceding paragraph, wherein the aromatic solvent is an optionally substituted pyridine. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak ezofagusa.
is an antibody or antibody fragment coupled to an effector molecule which mediates a therapeutic effect, such as an immune effector molecule, a toxin or a radioisotope. 
(ili) protutijelo ili fragment protutijela konjugiran s efektorskom molekulom koja provodi terapijski učinak, poput imunosne efektorske molekule, toksina ili radioizotopa.
The PET container of claim 3 wherein the density of the wall is greater than about 1.375 g/cc. 
PET posuda iz patentnog zahtjeva 1 ili 2 gdje je gustoća zida većaod 1.375 g/cc, poželjno oko 1.385 g/cc.
The lock according to claim 11, further comprising spacer plates, center openings of which are shaped to correspond to shape of a profile of the key. 
Brava prema zahtjevu 1, naznačena time, da ona obuhvaća razdvojne pločice (13) čiji su centralni otvori oblikovani tako da odgovaraju oblicima profila ključa.
The reaction mixture is heated under reflux for 1 h. 
Reakcijsku smjesu se grije 1 sat na refluksu.
m and q are each independently, 0 or an integer from 1 to 5; and p is 0.1, or 2, provided that when X is p-halophenyl, p-nitrophenyl, p-cyanophenyl, p-(methoxymethyl)phenyl, p-(benzamido)phenyl, a substituted p-(benzamido)phenyl, or p-carboxyphenyl, Y is not a substituted or unsubstituted phenyl, an unsubstituted furyl, a substituted or an unsubstituted thiophenyl, a substituted benzo[b]thiophenyl, an unsubstituted thiazolyl, a substituted 7,8-dihydronaphthyl, a substituted pyrazinyl, or a substituted or unsubstituted pyridinyl; 
m i q su svaki nezavisno, 0 ili cijeli broj od 1 do 5; i p je 0,1, ili 2, pod uvjetom da kada X je p-halofenil, p-nitrofenil, p-cijanofenil, p-(metoksimetil)fenil, p-(benzamido)fenil, supstituirani p- (benzamido)fenil, ili p-karboksifenil, Y nije supstituirani ili nesupstituirani fenil, nesupstituirani furil, supstituirani ili nesupstituirani tiofenil, supstituirani benzo[b]tiofenil, nesupstituirani tiazolil, supstituirani 7,8-dihidronaftil, supstituirani pirazinil, ili supstituirani ili nesupstituirani piridinil;
A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1, a pharmaceutically acceptable carrier and optionally one or more additional therapeutic agents selected from the group consisting of a chemotherapeutic agent, anti-inflammatory agents, and analgesics. 
Farmaceutski pripravak koji obuhvaća antitijelo ili fragment koji se vezuje za antigen prema patentnom zahtjevu 1, farmaceutski prihvatljivi nosač i opcionalno jedno ili više dodatnih terapijskih sredstava odabranih iz skupine koja se sastoji od kemoterapijskog sredstva, protuupalnih sredstava i analgetika.
A kit for isothermally amplifying a double-stranded nucleic acid target molecule comprising: 
Izotermni postupak amplifikacije ciljne molekule dvolančane nukleinske kiseline sadrži slijedeće korake:
A compound of the formula (Ia) or one of the salts thereof, solvates thereof or the solvates of salts thereof. 
Spoj s formulom (Ia) [image] ili jedna od njegovih soli, njegovi solvati ili solvati njegovih soli.
The combined ether extract was dried (MgSO4), filtered and evaporated under vacuum to an oil, which solidified on standing. 
Spojeni eterski ekstrakt se suši (MgSOy), filtrira se i ispari u vakuumu do ulja, koje skrutnjava stajanjem.
A compound which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, or a pharmaceutically acceptable salt or hydrate thereof. 
Spoj, naznačen time što je 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-on, ili farmaceutski prihvatljiva sol ili njegov hidrat.
The system of any preceding claim, wherein the filtration means (7) comprises a cartridge filter, sand filter, micro-filter, ultra-filter, nano-filter, or a combination thereof. 
Uređaj iz bilo kojeg od patentnih zahtjeva 7 do 12, pri čemu sredstvo za filtriranje obuhvaća kasetni filtar, pješčani filtar, mikro-filtar, ultra-filtar, nano-filtar ili njihovu kombinaciju.
A combination product comprising a muscarinic receptor agonist and an inhibitor of thyroid hormone synthesis, or a prodrug thereof, for a grouped or separate administration to a subject, simultaneously or sequentially. 
Sastav obuhvaća agonista muskarinskih receptora odabranog iz grupe koja se sastoji od pilokarpina, cevimelina, karbakola, metakolina i betanekola, ili njihovih soli, i inhibitora sinteze hormona štitnjače odabranog iz grupe koja se sastoji od metimazola, karbimazola, propiltiouracila i amiodarona, ili njihovih soli, i farmaceutski prihvatljivi nosač ili ekscipijens.
The aqueous suspension according to claim 4 wherein said buffering agent is chosen from sodium citrate, lactic acid and their mixtures. 
Vodena suspenzija prema zahtjevu 3, naznačena time što je navedeno sredstvo za puferiranje odabrano iz skupine koja sadrži natrijev citrat, mliječnu kiselinu i njihove smjese.
Heparinized plasma was diluted with phosphate-buffered saline solution (PBS) containing 0.16 M NaCl and the oxidation was started by 50 µM CuSO4. 
Heparinizirana plazma je razrijeđena s fosfatno puferiranom otopinom soli (PBS) koja je sadržavala 0,16 M NaC1 i oksidacija je započeta s 50 uM CuSOx.
In one embodiment, Polymorph A exhibits an X-ray powder diffraction pattern having one or more characteristic peaks expressed in degrees 2-theta at 3.9 +/- 0.3 degrees, 17.5 +/- 0.3 degrees, and 22.0 +/- 0.3 degrees 2-theta. 
Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima one ili more karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +H/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
The nucleic acid molecule of claim 1, wherein the antibody or antigen-binding fragment thereof comprises the variable heavy chain (VH) polypeptide of SEQ ID NO:25 and the variable light chain (VL) polypeptide of SEQ ID NO:29. 
Antitijelo ili antigen-vezujući fragment istog prema zahtjevu 1, pri čemu spomenuto antitijelo ili antigen-vezujući fragment istog sadrži sekvence amino kiselina iz: SEQ ID NO: 25 i SEQ ID NO: 29.
sending (503), by the base station, the ul grant to a user terminal; wherein the uplink resource index is one of a plurality of uplink resource indices, each of the plurality of uplink resource indices corresponds to either one group of one uplink subframe or one group of two uplink subframes, at least one of the plurality of uplink resource indices corresponds to one group of one uplink subframe, at least another one of the plurality of uplink resource indices corresponds to one group of two uplink subframes, and the uplink subframes in each group are not completely the same. 
Korisnički terminal, koji sadrži modul za primanje instrukcije (801), koji je prilagođen za primanje naznake odobrenja resursa za uzlaznu vezu, odobrenja uzlazne veze, od bazne stanice, BS, naznačen time da odobrenje uzlazne veze prenosi indeks resursa za uzlaznu vezu, indeks resursa za uzlaznu vezu je odgovarajući sa barem jednim resursom za uzlaznu vezu u smislu porijekla, odgovarajuća povezanost je određena sa omjerima uzlazno-silaznih podokvira konfiguracije, a broj uzlaznih podokvira je veći nego broj silaznih podokvira u omjeru uzlazno-silaznih podokvira konfiguracije;
A covering, in particular a floor covering, consisting of mutually coupled panels as claimed in claim 1 . A method of assembling interconnectable panels as claimed in claim 1, for forming a covering, comprising the steps of: 
Pokrov, posebno podni pokrov, koji se sastoji od međusobno povezanih ploča (1, 42, 43, 46, 53, 57) u skladu s bilo kojim od prethodnih patentnih zahtjeva.
The compound or salt according to claim 5 wherein R2a represents isopropoxy. The compound or salt according to claim 4 wherein R2 represents SO2R2b and R2b represents methyl, ethyl, propyl, cyclopropyl, —N(CH3)2 or —N(C2H5)2. 
Spoj ili sol u skladu s patentni zahtjevom 3, naznačen time što R" predstavlja SO;R" i R" predstavlja metil, etil, propil, ciklopropil, -N(CH:), ili -N(C>Hs),.
The device according to claim 7, characterized in that said flat perforated plate (35) has a perforated surface ranging from 20% to 5% of the overall surface of the flat plate (35). 
Uređaj u skladu s patentnim zahtjevom 6, naznačen time što navedena ravna perforirana ploča (35) ima perforiranu površinu u rasponu od 20% do 5% od ukupne površine ravne ploče (35).
formulating the GPR119 agonist having the effect of a GLP-1 secretagogue with a pharmaceutically acceptable carrier as a pharmaceutical composition. 
Postupak identifikacije GPR119 agonista koji imaju učinak GLP-1 sekretogoga, naznačen time, da obuhvaća
A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier in a form suitable for oral administration. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 2 i farmaceutski prihvatljiv nosač.
The dietary supplement according to claim 1, in the form of capsule or sachet. 
Nadomjestak prema patentnim zahtjevima 1-8, naznačen time da je u obliku kapsula ili vrećica.
One particular acid from which acid addition salts may be formed is methanesulphonic acid. 
Kisclinske adicijske soli se naročito mogu formirati s metansulfonskom kiselinom.
The energy in these cavities is higher than the activation barrier and triggers the phase transformation. 
Energija tih šupljina je veća o aktivacijske barijere i potiče fazu transformacije.
2 shows an apparatus for the implementation of the method for intensification of production of high-viscosity oils. 
Slika 2 prikazuje uređaj za primjenu postupka povećanja proizvodnje naftu visoke viskoznosti.
The patient medical record may be maintained by a laboratory, physician's office, a hospital, a health maintenance organization, an insurance company, or a personal medical record website. 
Postupak prema patentnom zahtjevu 13, naznačen time što medicinsku dokumentaciju pacijenta vodi laboratorij, ured zaduženog liječnika, bolnica, zdravstvena organizacija, osiguravajuće društvo ili služba internet stranice za osobne zdravstvene kartone.
a VH region as depicted in SEQ ID NO: 57, and a VL region as depicted in SEQ ID NO: 58; 
57,i VL regiju kao što je prikazano u SEQ ID NO: 67,1 VL regiju kao što je prikazano u SEQ ID NO:
8 a - c the base unit 3 is shown without the collapsible container 2 attached, to allow a better view of the internal parts of the base unit 3 . 
Na slikama 8a-c osnovni dio 3 je prikazan bez priključenog sklopivog spremnika 2, da se bolje vide unutarnji dijelovi osnovne jedinice 3.
Upon dissolution, the mixture has been stirred for 3 hours to homogenize. 
Nakon otapanja, smjesa je miješana tijekom 3 sata kako bi se homogenizirala.
To this end, a subject of the present invention is a process for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, and the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: 
HR P20181206 T1 PATENTNI ZAHTJEVI Postupak za proizvodnju, na industrijskoj razini, kapsularnog polisaharida Haemophilus influenzae tipa b (PRP) namijenjenog za potrebe cjepiva, prema kojem se soj Haemophilus influenzae tipa b (Hib) kultivira u mediju za kultiviranje, a supernatant kulture se sakuplja 1 obrađuje kako bi se iz njega ekstrahirao kapsularni polisaharid, te navedeni medij za kultiviranje sadrži barem:
providing interior equipment within said cuboid shape; providing the module with engagement means for engagement with prefabricated panels or slabs or other prefabricated modules by means of connecting devices; and 
(vi) pružajući prethodno proizvedeni modul (2) s prethodno montiranim sredstvima djelovanja za kasnije djelovanje s prethodno proizvedenim panelima ili pločama ili drugim prethodno proizvedenim modulima pomoću povezivanja uređaja, i
The Jak1 and/or Jak2 inhibitor for use according to claim 1 or 2, wherein the inhibitor is AG490 with the CAS No. 
Jak1 i/ili Jak2 inhibitor za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je inhibitor AG490 s CAS br.
Use of the depot formulation of the present invention is typically for treatment of chronic viral infections and prevention of chronic viral reinfection. Preferably use of the depot formulation of the present invention is for viral infections selected from the group consisting of hepatitis B and HIV infections, and most preferably the group consisting of hepatitis B infections. 
Depo formulacija u skladu sa bilo kojim od prethodnih patentnih zahtjeva za primjenu u liječenju kroničnih virusnih infekcija i prevenciji kronične virusne reinfekcije poželjno odabrane od grupe infekcija koja se sastoji od hepatitisa B i HIV infekcija, i najpoželjnije grupe koja se sastoji od infekcija hepatitisom B.
As a further option the water outlet and the steam outlet can be provided with hot water from the thermoblocks. 
Kao slijedeći izbor, može se ugraditi izlaz za vodu 1 izlaz za vodenu paru, s vrućom vodom iz termoblokova.
The composition according to any of claims 1 to 5, wherein the specific surface area of said pharmaceutically acceptable carrier is 250-1000 m2/g. 
miješanje dobivene superzasićene otopine iz koraka a) sa amorfnim silicijevim dioksidom koji ima specifičnu površinu od najmanje 250 m2/g.
While the compounds of the present invention can be administered as the sole active pharmaceutical agent (i.e., mono-therapy), they can also be used in combination with other pharmaceutical agents (i.e., combination-therapy), such as, for the treatment of the diseases/conditions/disorders described herein. 
Dod se spojevi prikazanog izuma mogu primijeniti kao samostalno aktivno farmaceutsko sredstvo (mono-terapija), mogu se također koristiti u kombinaciji s ostalim farmaceutskim sredstvima (kombinirana-terapija), kao što je u slučaju liječenja bolesti/stanja/poremećaja opisanih u ovom tekstu.
Therefore, in one aspect, the invention provides a method of treatment, prevention or alleviation of obesity, or an obesity associated disorder, and for treatment, prevention or alleviation of the cardiovascular side effects of Tesofensine, in a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of Tesofensine, or a pharmaceutically acceptable salt thereof; in a combination therapy with Metoprolol, or a pharmaceutically acceptable salt thereof. 
PATENTNI ZAHTJEVI Kombinacija tesofenzina, ili njegove farmaceutski prihvatljive soli i metoprolola, ili njegove farmaceutski prihvatljive soli, naznačena time što je za uporabu za liječenje, prevenciju 1li ublažavanje pretilosti ili poremećaja povezanog s pretilošću odabrano iz skupine koju čine poremećaji prejedanja, bulimija nervosa, poremećaj prejedanja, kompulzivno prekomjerno jedenje, smanjena regulacija apetita, metabolički sindrom, dijabetes tipa 2, dislipidemija, ateroskleroza i pretilost inducirana lijekom u živom životinjskom tijelu, te za prevenciju ili ublažavanje kardiovaskularnih nuspojava tesofenzina.
Reaction of compounds of formula XVI with a compound of formula XV, hydrazine for example (where R4 is hydrogen), in a solvent such as DMF, water or THF, or in the absence of cosolvent gives a compound of formula XIV. 
Reakcija spoja formule XVI sa spojem formule XV, npr., hidrazinom (gdje je R" vodik), u otapalu kao što je DMF, voda ili THF, ili u odsutnosti pomoćnog otapala daje spoj formule XIV.
A compound according to any of paragraphs 1 to 9, wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
the card remove feature is a recess (12) in the housing opposite each card opening (3), which offers sufficient space to push with a finger the present cards through the card opening (3) partly outside the housing; the card remove feature comprises a stepped element (16), which can by the user relative to the housing be moved against the side of the within the housing present card stack, resulting that this stack in a stepped shape partly moves outside the housing; 
Držač za kartice sukladno bilo kojem od prethodnih zahtjeva, pri čemu element za uklanjanje kartica obuhvaća stepenasti element (16), koji može ukloniti korisnik u odnosu na stranu unutar kućišta na kojoj se nalazi niz kartica, kao rezultat se taj niz u stepenastom obliku pomiče dijelom izvan kućišta, pri čemu je od tri uzastopne stube srednja stuba slobodna od djelovanja karticom guranjem izvana.
Sustainable system for treating a body of water affected by bacteria and microalgae at low cost, the system comprising: 
PATENTNI ZAHTJEVI 1. - Veliko umjetno vodeno tijelo na koje utječu bakterije i mikroalge 1 sustav za njegovu obradu i održavanje uz niske troškove, te obuhvaća:
A compound of formula (I) or a salt or solvate thereof: for use in the treatment of ocular neovascular disorders by topical administration directly to the eye. 
. Spoj formule (1) ili njegova sol ili solvat: naznačen time što je namijenjen liječenju neovaskularnih poremećaja oka topikalnom primjenom izravno u oko.
In fact, acceptable results are obtained only when the crosslinked PMMA particle size is less than 200 micron diameter. 
U stvari, dobiju se prihvatljivi rezultati samo ako su dimenzije čestica umreženog PMMA manje 0d 200 mikrona u promjeru.
The method according to one or more of the preceding claims 15 to 21, comprising providing said first rows of knitting (1) by way of a double-coated elastomer yarn (1a). 
Postupak prema jednom ili više prethodnih zahtjeva 15 do 21, naznačen time, da on obuhvaća izradu spomenutih neparnih redova pletenja (1) od dvostruko prevučenog elastomernog konca (1a).
B is the B-chain of insulin lispro (SEQ ID NO: 3); and wherein A and B are properly cross-linked and P is attached via an urethane covalent bond to the epsilon-amino group of the lysine at position 28 of B; 
B je B-lanac inzulina lispro (SEQ ID NO: 3); i gdje A i B su ispravno ukriženo povezani, a P je vezan preko uretanske kovalentne veze na e-amino skupinu lizina na položaju 28 u B;
An expression vector, encoding the antibody of claim 1, comprising a nucleic acid sequence selected from the group consisting of: 
Ekspresijski vektor koji kodira protutijelo iz patentnog zahtjeva 1, sadrži slijed nukleinskih kiselina opisan u SEQ
one or more pharmaceutically acceptable excipients, diluents or carriers; and a therapeutically effective amount of insulin lispro. 
jednu ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili podloga; i terapijski djelotvornu količinu inzulina lispro.